Searching. Please wait…
1583
37
170
29013
4402
2599
347
386
Abstract: Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and T?? cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients.
Fuente: Life, 2023, 13(2), 419
Publisher: MDPI
Year of publication: 2023
No. of pages: 13
Publication type: Article
DOI: 10.3390/life13020419
ISSN: 2075-1729
Publication Url: https://doi.org/10.3390/life13020419
Consult in UCrea Read publication
OLVEIRA, ANTONIO
AUGUSTIN, SALVADOR
BENLLOCH, SALVADOR
AMPUERO, JAVIER
SUÁREZ-PÉREZ, JORGE ALONSO
SUSANA ARMESTO ALONSO
VILARRASA, EVA
BELINCHÓN-ROMERO, ISABEL
HERRANZ, PEDRO
JAVIER CRESPO GARCIA
GUIMERÁ, FRANCISCO
GÓMEZ-LABRADOR, LARA
MARTÍN, VÍCTOR
CARRASCOSA, JOSÉ MANUEL
Back